Lawrence Otto Klein - 05 Jul 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: Director
Issuer ticker: DYN
Reported as of: 05 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2022, 18:20:16 UTC
Prior SEC filing: 06 Jun 2022
Next SEC filing: 18 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Richard Scalzo, Attorney-in-Fact

Key filing fact

Lawrence Otto Klein filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 06 Jul 2022.

Key facts

This page summarizes Lawrence Otto Klein's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2022, 18:20.

Change

Previous filing in this sequence was filed on 06 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DYN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,222
Change %
Price: $0.000000
Shares after: 7,222
Date: 05 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,222
Exercise price: $5.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.